Company news
Nextcure, Inc. (NASDAQ:NXTC) news
Nextcure, Inc. news releases on 6ix. Latest, Aug 6, 2026: NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
Press releases & updates
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
August 6, 2026
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
July 14, 2026
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
June 3, 2026
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
June 1, 2026
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
May 7, 2026
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
May 4, 2026
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
April 7, 2026
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
March 31, 2026
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
March 4, 2026
NextCure Provides Business Update
January 23, 2026
NextCure Provides Business Update
January 22, 2026
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
November 20, 2025
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
November 17, 2025
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
November 12, 2025
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
November 5, 2025
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
October 16, 2025
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
August 7, 2025
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
July 24, 2025
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
June 16, 2025
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
May 29, 2025
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
May 1, 2025
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
April 4, 2025
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
March 6, 2025
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
January 9, 2025
NextCure Announces Acceptance of IND Application for LNCB74
December 9, 2024
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
November 6, 2024
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
November 4, 2024
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
July 31, 2024
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
May 29, 2024
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
May 1, 2024
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
April 23, 2024
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
April 3, 2024
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
March 20, 2024
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
March 4, 2024
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
January 17, 2024
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
December 20, 2023
NextCure Provides Year-End Clinical Pipeline Updates
December 13, 2023
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
November 14, 2023
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
November 1, 2023
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
September 25, 2023
NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
August 2, 2023
NextCure Provides Business Update and Reports First Quarter 2023 Financial Results
May 3, 2023
NextCure Provides Business Update and Reports Full Year 2022 Financial Results
March 1, 2023
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
November 14, 2022
NextCure Provides Update and Reports Third Quarter 2022 Financial Results
November 2, 2022
NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
October 26, 2022
NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors
October 3, 2022
NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
August 3, 2022
NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation
July 5, 2022